A single-arm, open-label, multi-center study of complete molecular response (CMR) in patients with newly diagnosed Philadelphia-chromosome positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.


TPS204 Background: With more potent tyrosine kinase inhibitors, increasingly sensitive methods are required to monitor treatment response and quantify minimal residual disease (MRD). Molecular monitoring is recommended by National Comprehensive Cancer Network and European LeukemiaNet guidelines; major molecular response (MMR) correlates with optimal long… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics